First-in-human study of THB335, an oral small molecule inhibitor of Wild Type KIT Receptor Tyrosine Kinase: Initial Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Results from Single Ascending Dose Cohorts (AAAAI-WAO 2025) - Feb 11, 2025 - Abstract #673; Pres time: Mar 2, 2025; 09:45 AM - 10:45 AM; Location: Convention Center, Ground Level, Hall A; "Conclusions A single oral dose of THB335 in healthy participants was well-tolerated across doses. The MAD cohorts are underway, and data will be forthcoming."
Clinical • P1 data • PK/PD data • Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Urticaria
|
|
Nathan Bachtell 1; Sandra Pagnussatt 2; Sherri Smith 1; Sujatha Kumar 1; Amy DiRico 1; Tess Schmalbach 3; Sammie Rivera 1; Ted Snyder 1; Edward Conner 4
|